Find all the latest content on TAVI published on this website.

TAVI, now an established, valid treatment for patients presenting with symptomatic severe aortic stenosis, has proven to be superior to medical treatment for inoperable patients whilst being a valid alternative to surgery in select, high-risk patients....

This session addresses complex complications during vascular access with a focus on retrograde removal of broken sheaths. Learn to recognize critical signs, manage rare but severe complications including broken guidewires in the radial artery, and explore innovative off-label solutions for challenging scenarios.

Watch this session if you want to get an overview of the most recent clinical evidence regarding large bore closure devices and participate in a critical discussion on the most relevant clinical data and best practices in large bore management.

Discover the latest evidence on the Supraflex thin-strut sirolimus DES in complex cases—from small vessels and diabetes to STEMI—supported by OCT analysis. This session highlights Supraflex’s performance in high bleeding risk and elderly patients, featuring data from FIRE, COMPARE, EARTH HBR, and Cruz Senior studies. Get...

This hotline session provides a comprehensive overview of the latest clinical data on new coronary devices, including bioresorbable scaffolds, drug-coated balloons, and drug-eluting stents. Participants will learn about the outcomes of various randomized trials and registry studies, examining the performance of these innovative technologies in different...

Large-bore femoral access closure remains a critical step in transfemoral TAVI, where access-site complications can significantly impact outcomes.

This My Toolkit article presents a step-by-step tutorial on a combined suture- and plug-based closure strategy using one ProStyle™ and one Angio-Seal®. The technique aims to achieve rapid, reliable...

This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.

Who better to recount its history than the inaugural President of the Euro4C Group? Additionally, insights are provided by the Chairman of PCR, the former EAPCI President, and a pivotal member of the editorial team.

Professor David J. Cohen presented the results of the economic outcomes of the PARTNER 3 trial on Friday, 5 November, in the Late-Breaking Trial session of the Transcatheter Cardiovascular Therapeutics Congress 2021. Giuseppe Biondi-Zoccai provides his analysis of this study.

The main goal of the randomized GUIDE-HF trial was to assess the ability of continuous PAP monitoring to improve outcomes in patients with heart failure NYHA class II-IV and a HF hospitalization within previous 12 months or elevated BNP/NT-proBNP. 

The humble and noble ambition of SHARE (Sustain Health development in Africa through Responsible Education) is to identify a favorable environment in sub-Saharan countries where catheter labs can be established.

Paris, France 17 May 2022 – On the 19th of May the Andreas Grüntzig Ethica Award, the highest honour in the interventional cardiology community, will be awarded at EuroPCR 2022 to the Nurses and Allied Professionals community in recognition of the essential role they play in...

Watch this EuroIntervention image to learn how the collision of a TAV device during valve crossing in ViV TAVI can potentially cause instability or dehiscence of the sutureless bioprosthesis, contributing to severe poorly tolerated PVL.

Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

Paris, France. 19 May 2022. We CARE, a joint initiative of PCR and Stent – Save a Life!, dedicated to restoring faith in cardiovascular healthcare and increasing awareness of the importance of timely and accessible treatment, is presenting a first study at EuroPCR 2022: a UK...